Intralesional Triamcinolone: Dosage, Technique, and Contraindications
Recommended Dosing and Technique
For most dermatologic conditions requiring intralesional triamcinolone, use concentrations of 5-10 mg/mL injected just beneath the dermis in the upper subcutis, with 0.05-0.1 mL per injection site producing approximately 0.5 cm diameter of effect 1.
Specific Dosing by Indication
Alopecia Areata:
- Concentration: 5-10 mg/mL triamcinolone acetonide (or 25 mg/mL hydrocortisone acetate as alternative)
- Volume: 0.05-0.1 mL per injection site
- Depth: Just beneath the dermis in the upper subcutis
- Frequency: Monthly injections
- Best candidates: Patchy hair loss with fewer than 5 patches <3 cm diameter, cosmetically sensitive sites like eyebrows
- Expected response: 62% achieve full regrowth; effects last approximately 9 months 1
Chalazion:
- Concentration: 40 mg/mL
- Dose: 2-6 mg depending on lesion size (typically 4 mg)
- Success rate: 81-83% complete resolution within 6 weeks
- Mean resolution time: 15.7 days
- Repeat injection: Only 2-8% require second injection 2, 3
Inflammatory Acne:
- Concentration: 0.1-0.2% (1-2 mg/mL)
- Higher concentration (0.2%): More effective for severe lesions
- Route: Direct intralesional injection into inflammatory lesion 4
Vitiligo (when combined with NB-UVB):
- Safest concentrations: 0.625-1.25 mg/mL
- More effective but higher risk: 2.5-5 mg/mL (causes epidermal atrophy and collagen disorganization)
- Frequency: Monthly for 6 sessions 5
Symptomatic Lipomas:
- Concentration: 40 mg/mL
- Dose: 40 mg for small lipomas (1-3 cm); 80 mg for large lipomas (4-6 cm)
- Effect: 60% mean reduction in size at 4 months; complete symptom resolution in all patients 6
Injection Technique
The key technical points are:
- Depth: Upper subcutis, just beneath the dermis—not too superficial (causes atrophy) or too deep (ineffective)
- Volume per site: 0.05-0.1 mL creates approximately 0.5 cm treatment zone
- Multiple injections: Can be given at same session; main limitation is patient discomfort 1
- Alternative delivery: Needleless devices (e.g., Dermajet) can be used, showing 62% response rate versus 7% with saline control 1
Important Contraindications and Precautions
Absolute Contraindications
- Active local infection at injection site
- Hypersensitivity to triamcinolone or formulation components
Relative Contraindications and Cautions
- Avoid ophthalmic use with topical formulations 7
- Infection risk: Discontinue if infection develops 7
- Systemic absorption: Limit total dose per session to minimize hypothalamic-pituitary-adrenal axis suppression
Common Adverse Effects by Concentration
Lower concentrations (0.625-1.25 mg/mL):
- Minimal side effects
- Safest profile 5
Standard concentrations (5-10 mg/mL):
- Patient discomfort (main limiting factor)
- Mild hypopigmentation (reported in some cases) 6
- Triamcinolone precipitates (11.5% incidence, self-resolving) 3
Higher concentrations (2.5-5 mg/mL or 40 mg/mL):
- Epidermal atrophy
- Dermal atrophy with visible skin depression
- Collagen fiber disorganization
- Hypopigmentation 5, 6
Critical Pitfalls to Avoid
- Injection too superficial: Causes visible skin atrophy and depigmentation—always inject in upper subcutis, not intradermally
- Excessive volume per site: Stick to 0.05-0.1 mL per injection to minimize atrophy risk
- Using high concentrations unnecessarily: Start with lower concentrations (5-10 mg/mL) for most conditions; reserve 40 mg/mL for specific indications like chalazion or lipomas
- Treating extensive disease: Intralesional therapy best suited for localized lesions; extensive disease requires systemic therapy
- Inadequate follow-up: Effects develop over days to weeks; schedule reassessment at 4-6 weeks
Storage and Handling
- Store at controlled room temperature 20-25°C (68-77°F)
- Avoid freezing 7
The evidence strongly supports intralesional triamcinolone as safe and effective when proper technique and dosing are followed, with the concentration and volume adjusted based on the specific condition being treated and anatomic considerations.